ESMI Study Group on "Imaging Mass Spectrometry - IMS"

CHANGE in LEADERSHIP

On behalf of founding members it is with pleasure to introduce the NEW CHAIRPERSONS of the STUDY GROUP on IMAGING MASS SPECTROMETRY composed of Jo Cappell, Tiffany Porta and Gregory Hamm.

"We are delighted to take on this new responsibility in the study group on imaging mass spectrometry (IMS). Over these last years, multimodality has played a major role in IMS application, which is why we would like to share our passion with other scientist from different fields of molecular imaging, considering why and how IMS can be integrated into other imaging workflows, initiating interesting and stimulating discussions during workshops and outside, increasing interaction between our group members, from new starters to expert users, sharing knowledge and experience and finally, providing a stimulating experience in interdisciplinary imaging.

You’re cordially invited to join our next f2f study group meeting during the European Molecular Imaging Meeting 2017 (5-7 April) in Cologne and participate in the workshop on mass spectrometry imaging which will be held already on Tuesday 4th April 2017 (6-7:30 pm). Of course, you can address any remarks to us or the ESMI office at any time."

Jo, Tiffany, and Gregory

Scope , relevance, and objectives

The scope of the Imaging MS study group is to provide a networking and dissemination platform for molecular imaging researchers and professionals that use mass spectrometry in their daily practice and enables connections to expert in other imaging disciplines.

Multimodal molecular imaging with mass spectrometry is a label-free imaging modality that has demonstrated enormous potential for pre-clinical and biomedical research. IMS combines the molecular analytic properties of MS with the spatial information obtained by traditional histology, thereby enabling molecular information to be correlated to tissue morphology. This correlation enables a deeper understanding of tissue complexity and the pathophysiological processes underlying disease. As such, IMS enables direct targeted and/or untargeted analysis of endogenous metabolites, oligosaccharides, lipids, peptide and proteins, as well as exogenous compounds (i.e. pharmaceuticals, anti-cancer drugs). The subsequent identification and quantification of potential markers can contribute to generating disease-specific molecular profiles.

This study group intends to increase the broader awareness of the technological basis, as well as its clinical and pharmaceutical applications. The study group fosters a knowledge base where people can learn about quantitative aspects and considerations of imaging MS as well as the potential for integration with other imaging modalities such as PET or MRI. The study group welcomes members with an interest in multimodal imaging that allow researchers to explore truly interdisciplinary molecular research.

The group currently comprises of academic and industrial collaborators expert in various imaging MS-based technologies, fundamental and applied to pre-clinical and clinical research, and strongly encourages interdisciplinary interactions and therefore welcome all members with an interest in other multimodal imaging to join the discussions initiated during the dedicated workshop or during the different sessions.

Objectives

  • Enable dissemination of imaging MS-based ideas, methods, techniques, protocols and applications.
  • Stimulate interactions with the broader molecular imaging community and integration with other imaging modalities.
  • Ensure COST networking activities (COST Action BM1104) are continued in the ESMI professional environment.